HeimBSX • NYSE
add
Boston Scientific Corp
102,71 $
Eftir lokun(0,00%)0,00
102,71 $
Lokað: 12. sep., 16:32:01 GMT-4 · USD · NYSE · Lagalegir fyrirvarar
Við síðustu lokun
104,34 $
Dagbil
102,48 $ - 104,43 $
Árabil
80,64 $ - 109,50 $
Markaðsvirði
152,19 ma. USD
Meðalmagn
6,27 m.
V/H-hlutf.
61,15
A/V-hlutfall
-
Aðalkauphöll
NYSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | jún. 2025info | Breyting á/á |
---|---|---|
Tekjur | 5,06 ma. | 22,84% |
Rekstrarkostnaður | 2,47 ma. | 20,81% |
Nettótekjur | 797,00 m. | 145,99% |
Hagnaðarhlutfall | 15,75 | 100,38% |
Hagnaður á hvern hlut | 0,75 | 20,97% |
EBITDA | 1,28 ma. | 15,23% |
Virkt skatthlutfall | 15,52% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | jún. 2025info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 534,00 m. | -81,67% |
Heildareignir | 41,56 ma. | 11,99% |
Heildarskuldir | 18,91 ma. | 14,59% |
Eigið fé alls | 22,65 ma. | — |
Útistandandi hlutabréf | 1,48 ma. | — |
Eiginfjárgengi | 6,89 | — |
Arðsemi eigna | 5,77% | — |
Ávöxtun eigin fjár | 6,85% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | jún. 2025info | Breyting á/á |
---|---|---|
Nettótekjur | 797,00 m. | 145,99% |
Handbært fé frá rekstri | 1,29 ma. | 58,18% |
Reiðufé frá fjárfestingum | -1,13 ma. | -315,50% |
Reiðufé frá fjármögnun | -340,00 m. | -1.516,67% |
Breyting á handbæru fé | -178,00 m. | -131,45% |
Frjálst peningaflæði | 1,16 ma. | 111,56% |
Um
Boston Scientific Corporation, is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
Framkvæmdastjóri
Stofnsett
29. jún. 1979
Höfuðstöðvar
Vefsvæði
Starfsfólk
53.000